SubscribeGet APP
Pharmaceuticals

How the vaccine developed by Oxford University stacks up against Pfizer and Moderna

​Up to 90 percent effectiveAFP
1/6
​Up to 90 percent effective
According to a report by AP, AstraZeneca said November 23 that late-stage trials showed its coronavirus vaccine was up to 90% effective, giving public health officials hope they may soon have access to a vaccine that is easier to distribute than some of its rivals. The results are based on interim analysis of trials in the U.K. and Brazil of a vaccine developed by Oxford University and manufactured by AstraZeneca. No hospitalizations or severe cases of COVID-19 were reported in those receiving the vaccine.
​Competing with Pfizer and ModernaAFP
2/6
​Competing with Pfizer and Moderna
AstraZeneca is the third major drug company to report late-stage results for its potential COVID-19 vaccine as the world anxiously waits for vaccines that will end the pandemic that has killed almost 1.4 million people. Pfizer and Moderna last week reported preliminary results from late-stage trials showing their vaccines were almost 95% effective.
​Easier distributionAFP
3/6
​Easier distribution
Unlike the Pfizer and Moderna vaccines, the Oxford-AstraZeneca candidate doesn't have to be stored at ultra-cold temperatures, making it easier to distribute, especially in developing countries. All three vaccines must be approved by regulators before they can be widely distributed.
​Targeting low-income countriesAFP
4/6
​Targeting low-income countries
AstraZeneca said it will immediately apply for early approval of the vaccine where possible, and it will seek an emergency use listing from the World Health Organization, so it can make the vaccine available in low-income countries.
​Average efficacy 70%AP
5/6
​Average efficacy 70%
The AstraZeneca trial looked at two different dosing regimens. A half-dose of the vaccine followed by a full dose at least one month later was 90% effective. Another approach, giving patients two full doses one month apart, was 62% effective. The combined results showed an average efficacy rate of 70%.
​How it worksReuters
6/6
​How it works
The vaccine uses a weakened version of a common cold virus that is combined with genetic material for the characteristic spike protein of the virus that causes COVID-19. After vaccination, the spike protein primes the immune system to attack the virus if it later infects the body.

*

Success
This article has been saved